BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kumagi T, Heathcote EJ. Primary biliary cirrhosis. Orphanet J Rare Dis 2008;3:1. [PMID: 18215315 DOI: 10.1186/1750-1172-3-1] [Cited by in Crossref: 67] [Cited by in F6Publishing: 57] [Article Influence: 4.8] [Reference Citation Analysis]
Number Citing Articles
1 Ciesek S, Becker T, Manns MP, Strassburg CP. Anti-parietal cell autoantibodies (PCA) in primary biliary cirrhosis: a putative marker for recurrence after orthotopic liver transplantation? Annals of Hepatology 2010;9:181-5. [DOI: 10.1016/s1665-2681(19)31659-x] [Cited by in Crossref: 4] [Article Influence: 0.3] [Reference Citation Analysis]
2 Koutsoumpas AL, Kriese S, Rigopoulou EI. Popular and unpopular infectious agents linked to primary biliary cirrhosis. Auto Immun Highlights 2012;3:95-104. [PMID: 26000132 DOI: 10.1007/s13317-012-0039-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
3 Boyd A, Cain O, Chauhan A, Webb GJ. Medical liver biopsy: background, indications, procedure and histopathology. Frontline Gastroenterol 2020;11:40-7. [PMID: 31885839 DOI: 10.1136/flgastro-2018-101139] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
4 Azemoto N, Kumagi T, Abe M, Konishi I, Matsuura B, Hiasa Y, Onji M. Biochemical response to ursodeoxycholic acid predicts long-term outcome in Japanese patients with primary biliary cirrhosis: Biochemical response to UDCA in PBC. Hepatology Research 2011;41:310-7. [DOI: 10.1111/j.1872-034x.2011.00782.x] [Cited by in Crossref: 35] [Cited by in F6Publishing: 7] [Article Influence: 3.2] [Reference Citation Analysis]
5 Hua F, Wang L, Rong X, Hu Y, Zhang JM, He W, Zhang FC. Elevation of Vδ1 T cells in peripheral blood and livers of patients with primary biliary cholangitis. Clin Exp Immunol 2016;186:347-55. [PMID: 27543908 DOI: 10.1111/cei.12852] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
6 De Marino S, Ummarino R, D'Auria MV, Chini MG, Bifulco G, D'Amore C, Renga B, Mencarelli A, Petek S, Fiorucci S, Zampella A. 4-Methylenesterols from Theonella swinhoei sponge are natural pregnane-X-receptor agonists and farnesoid-X-receptor antagonists that modulate innate immunity. Steroids 2012;77:484-95. [PMID: 22285937 DOI: 10.1016/j.steroids.2012.01.006] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 3.3] [Reference Citation Analysis]
7 Hirschfield GM, Al-Harthi N, Heathcote EJ. Current status of therapy in autoimmune liver disease. Therap Adv Gastroenterol. 2009;2:11-28. [PMID: 21180531 DOI: 10.1177/1756283x08098966] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
8 Huesmann M, Huesmann T, Osada N, Phan NQ, Kremer AE, Ständer S. Cholestatic pruritus: a retrospective analysis on clinical characteristics and treatment response. J Dtsch Dermatol Ges. 2013;11:158-168. [PMID: 23190476 DOI: 10.1111/j.1610-0387.2012.08028.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
9 Smyk D, Rigopoulou EI, Baum H, Burroughs AK, Vergani D, Bogdanos DP. Autoimmunity and environment: am I at risk? Clin Rev Allergy Immunol. 2012;42:199-212. [PMID: 21337133 DOI: 10.1007/s12016-011-8259-x] [Cited by in Crossref: 44] [Cited by in F6Publishing: 42] [Article Influence: 4.4] [Reference Citation Analysis]
10 Arjas E, Gasbarra D. Adaptive treatment allocation and selection in multi-arm clinical trials: a Bayesian perspective. BMC Med Res Methodol 2022;22. [DOI: 10.1186/s12874-022-01526-8] [Reference Citation Analysis]
11 Yang GX, Wu Y, Tsukamoto H, Leung PS, Lian ZX, Rainbow DB, Hunter KM, Morris GA, Lyons PA, Peterson LB, Wicker LS, Gershwin ME, Ridgway WM. CD8 T cells mediate direct biliary ductule damage in nonobese diabetic autoimmune biliary disease. J Immunol 2011;186:1259-67. [PMID: 21169553 DOI: 10.4049/jimmunol.1001597] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 2.6] [Reference Citation Analysis]
12 Lee DH, Huh SJ, Yoon HH, Lee SW, Kim KH, Kim SH. Clinical significance of anti-mitochondrial antibodies in a patient with chronic graft-versus-host disease following hematopoietic stem cell transplantation. Korean J Hematol 2011;46:200-2. [PMID: 22065977 DOI: 10.5045/kjh.2011.46.3.200] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
13 Li A, Wang Y, Deng Z. Concurrent autoimmune pancreatitis and primary biliary cirrhosis: a rare case report and literature review. BMC Gastroenterol. 2014;14:10. [PMID: 24410827 DOI: 10.1186/1471-230X-14-10] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
14 Pinto IP, Minasi LB, da Cruz AS, de Melo AV, da Cruz E Cunha DM, Pereira RR, Ribeiro CL, da Silva CC, de Melo E Silva D, da Cruz AD. A non-syndromic intellectual disability associated with a de novo microdeletion at 7q and 18p, microduplication at Xp, and 18q partial trisomy detected using chromosomal microarray analysis approach. Mol Cytogenet 2014;7:44. [PMID: 25028595 DOI: 10.1186/1755-8166-7-44] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
15 Milkiewicz M, Caballería L, Smyk DS, Milkiewicz P. Predicting and preventing autoimmunity: the case of anti-mitochondrial antibodies. Auto Immun Highlights 2012;3:105-12. [PMID: 26000133 DOI: 10.1007/s13317-012-0038-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
16 Arenas F, Hervías I, Sáez E, Melero S, Prieto J, Parés A, Medina JF. Promoter hypermethylation of the AE2/SLC4A2 gene in PBC. JHEP Rep 2019;1:145-53. [PMID: 32039364 DOI: 10.1016/j.jhepr.2019.05.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
17 Kumagi T, Onji M. Presentation and diagnosis of primary biliary cirrhosis in the 21st century. Clin Liver Dis 2008;12:243-59; vii. [PMID: 18456178 DOI: 10.1016/j.cld.2008.02.014] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
18 Bianchi I, Lleo A, Bernuzzi F, Caliari L, Smyk DS, Invernizzi P. The X-factor in primary biliary cirrhosis: monosomy X and xenobiotics. Auto Immun Highlights 2012;3:127-32. [PMID: 26000136 DOI: 10.1007/s13317-012-0043-2] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
19 Invernizzi P, Floreani A, Carbone M, Marzioni M, Craxi A, Muratori L, Vespasiani Gentilucci U, Gardini I, Gasbarrini A, Kruger P, Mennini FS, Ronco V, Lanati E, Canonico PL, Alvaro D. Primary Biliary Cholangitis: advances in management and treatment of the disease. Digestive and Liver Disease 2017;49:841-6. [DOI: 10.1016/j.dld.2017.05.001] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 3.2] [Reference Citation Analysis]
20 Peyrode C, Gouin F, Vidal A, Auzeloux P, Besse S, Dauplat MM, Askienazy S, Heymann D, Chezal JM, Redini F, Miot-Noirault E. A"Proteoglycan targeting strategy" for the scintigraphic imaging and monitoring of the swarm rat chondrosarcoma orthotopic model. Sarcoma 2011;2011:691608. [PMID: 21331335 DOI: 10.1155/2011/691608] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
21 Millsop JW, Wang EA, Fazel N. Etiology, evaluation, and management of xerostomia. Clinics in Dermatology 2017;35:468-76. [DOI: 10.1016/j.clindermatol.2017.06.010] [Cited by in Crossref: 43] [Cited by in F6Publishing: 26] [Article Influence: 8.6] [Reference Citation Analysis]
22 Smyk D, Rigopoulou EI, Bizzaro N, Bogdanos DP. Hair dyes as a risk for autoimmunity: from systemic lupus erythematosus to primary biliary cirrhosis. Auto Immun Highlights. 2013;4:1-9. [PMID: 26000137 DOI: 10.1007/s13317-011-0027-7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
23 Marzioni M, Bassanelli C, Ripellino C, Urbinati D, Alvaro D. Epidemiology of primary biliary cholangitis in Italy: Evidence from a real-world database. Dig Liver Dis. 2019;51:724-729. [PMID: 30584000 DOI: 10.1016/j.dld.2018.11.008] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
24 Veríssimo R, Leite de Sousa L, Carvalho TJ, Fidalgo P. Novel SLC12A3 mutation in Gitelman syndrome. BMJ Case Rep 2021;14:e238097. [PMID: 33462018 DOI: 10.1136/bcr-2020-238097] [Reference Citation Analysis]
25 Granito A, Yang W, Muratori L, Lim MJ, Nakajima A, Ferri S, Pappas G, Quarneti C, Bianchi FB, Bloch DB, Muratori P. PML Nuclear Body Component Sp140 Is a Novel Autoantigen in Primary Biliary Cirrhosis. American Journal of Gastroenterology 2010;105:125-31. [DOI: 10.1038/ajg.2009.596] [Cited by in Crossref: 51] [Cited by in F6Publishing: 55] [Article Influence: 4.3] [Reference Citation Analysis]
26 Al-Harthy N, Kumagi T. Natural history and management of primary biliary cirrhosis. Hepat Med. 2012;4:61-71. [PMID: 24367233 DOI: 10.2147/HMER.S25998] [Cited by in Crossref: 2] [Cited by in F6Publishing: 8] [Article Influence: 0.2] [Reference Citation Analysis]
27 Wang ZW, Wang Y, Wang BY, Ding YY, Li JP, Ma L, Zhang H. Clinical features of autoimmune liver disease. Shijie Huaren Xiaohua Zazhi 2011; 19(15): 1568-1573 [DOI: 10.11569/wcjd.v19.i15.1568] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
28 Zhang B, Hu M, Zhang P, Cao H, Wang Y, Wang Z, Su T. BAFF promotes regulatory T-cell apoptosis and blocks cytokine production by activating B cells in primary biliary cirrhosis. Braz J Med Biol Res 2013;46:433-9. [PMID: 23681290 DOI: 10.1590/1414-431X20132665] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
29 Al-balushi MS, Al-busaidi JZ, Al-daihani MS, Shafeeq MO, Hasson SS. Sero-prevalence of Helicobacter pylori infection among asymptomatic healthy Omani blood donors. Asian Pacific Journal of Tropical Disease 2013;3:146-9. [DOI: 10.1016/s2222-1808(13)60059-6] [Cited by in Crossref: 6] [Article Influence: 0.7] [Reference Citation Analysis]
30 Tong GD, Tang HH, Wei CS, Chen YJ, He JS, Zhou XZ, Zheng YJ, Zhou DQ. Efficacy of ursodeoxycholic acid combined with Tongdan Decoction () on immunological indices and histopathological changes in primary biliary cirrhosis patients. Chin J Integr Med. 2012;18:16-22. [PMID: 22231705 DOI: 10.1007/s11655-0112-0962-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
31 Smyk D, Rigopoulou EI, Zen Y, Abeles RD, Billinis C, Pares A, Bogdanos DP. Role for mycobacterial infection in pathogenesis of primary biliary cirrhosis? World J Gastroenterol 2012; 18(35): 4855-4865 [PMID: 23002357 DOI: 10.3748/wjg.v18.i35.4855] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
32 Hayter SM, Cook MC. Updated assessment of the prevalence, spectrum and case definition of autoimmune disease. Autoimmun Rev 2012;11:754-65. [PMID: 22387972 DOI: 10.1016/j.autrev.2012.02.001] [Cited by in Crossref: 213] [Cited by in F6Publishing: 199] [Article Influence: 21.3] [Reference Citation Analysis]
33 Smyk DS, Rigopoulou EI, Muratori L, Burroughs AK, Bogdanos DP. Smoking as a risk factor for autoimmune liver disease: what we can learn from primary biliary cirrhosis. Annals of Hepatology 2012;11:7-14. [DOI: 10.1016/s1665-2681(19)31481-4] [Cited by in Crossref: 25] [Article Influence: 2.5] [Reference Citation Analysis]
34 Lefton HB, Rosa A, Cohen M. Diagnosis and Epidemiology of Cirrhosis. Medical Clinics of North America 2009;93:787-99. [DOI: 10.1016/j.mcna.2009.03.002] [Cited by in Crossref: 59] [Cited by in F6Publishing: 52] [Article Influence: 4.5] [Reference Citation Analysis]
35 Sfakianaki O, Koulentaki M, Tzardi M, Tsangaridou E, Theodoropoulos PA, Castanas E, Kouroumalis EA. Peri-nuclear antibodies correlate with survival in Greek primary biliary cirrhosis patients. World J Gastroenterol 2010; 16(39): 4938-4943 [PMID: 20954280 DOI: 10.3748/wjg.v16.i39.4938] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
36 Reichert J, Araújo AJD, Gonçalves CMC, Godoy I, Chatkin JM, Sales MDPU, Santos SRRDA. Diretrizes para cessação do tabagismo - 2008. J bras pneumol 2008;34:845-80. [DOI: 10.1590/s1806-37132008001000014] [Cited by in Crossref: 58] [Cited by in F6Publishing: 30] [Article Influence: 4.1] [Reference Citation Analysis]
37 Mullin S, Rabah R, Malas S, Bitar A. Autoimmune Hepatitis Type 2 Associated With Positive Antimitochondrial Antibodies: An Overlap Syndrome? Clin Pediatr (Phila) 2016;55:479-82. [DOI: 10.1177/0009922815588980] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
38 Ortet C, Vale Costa L. "Listen to Your Immune System When It's Calling for You": Monitoring Autoimmune Diseases Using the iShU App. Sensors (Basel) 2022;22:3834. [PMID: 35632243 DOI: 10.3390/s22103834] [Reference Citation Analysis]
39 Stancheva-ivanova MK, Wuyts W, van Hul E, Radeva BI, Vazharova RV, Sokolov TP, Vladimirov BY, Apostolova MD, Kremensky IM. Clinical and molecular studies of EXT1/EXT2 in Bulgaria. J Inherit Metab Dis 2011;34:917-21. [DOI: 10.1007/s10545-011-9314-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
40 Chow S, Pong A. Adaptive Design Methods in Clinical Trials. Encyclopedia of Biopharmaceutical Statistics. Informa Healthcare; 2010. pp. 16-27. [DOI: 10.3109/9781439822463.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
41 Fraher AL. A toxic triangle of destructive leadership at Bristol Royal Infirmary: A study of organizational Munchausen syndrome by proxy. Leadership 2016;12:34-52. [DOI: 10.1177/1742715014544392] [Cited by in Crossref: 15] [Cited by in F6Publishing: 4] [Article Influence: 1.9] [Reference Citation Analysis]
42 Zhang HA, Wang BM, Zhang MF, Chang YX, Gong YX. Clinicopathological features of autoimmune hepatic diseases: an analysis of 28 cases. Shijie Huaren Xiaohua Zazhi 2008; 16(29): 3338-3342 [DOI: 10.11569/wcjd.v16.i29.3338] [Reference Citation Analysis]
43 Ngu JH, Gearry RB, Wright AJ, Stedman CAM. Low incidence and prevalence of primary biliary cirrhosis in Canterbury, New Zealand: a population-based study. Hepatol Int 2012;6:796-800. [DOI: 10.1007/s12072-011-9329-0] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
44 Ohira H, Watanabe H. Pathophysiology and recent findings of primary biliary cirrhosis complicated by systemic sclerosis: PBC complicated by systemic sclerosis. Hepatol Res 2014;44:377-83. [DOI: 10.1111/hepr.12285] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
45 Adorini L, Pruzanski M, Shapiro D. Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis. Drug Discov Today. 2012;17:988-997. [PMID: 22652341 DOI: 10.1016/j.drudis.2012.05.012] [Cited by in Crossref: 175] [Cited by in F6Publishing: 160] [Article Influence: 17.5] [Reference Citation Analysis]
46 Johnson AM, Akpan EJ, Kale S, Patel A. A Rare Case Presentation: Diagnosing Primary Biliary Cholangitis in a Male Patient With Concomitant Type 1 Diabetes. Cureus 2021;13:e16109. [PMID: 34367753 DOI: 10.7759/cureus.16109] [Reference Citation Analysis]
47 Smyk DS, Bogdanos DP, Mytilinaiou MG, Burroughs AK, Rigopoulou EI. Rheumatoid arthritis and primary biliary cirrhosis: cause, consequence, or coincidence? Arthritis 2012;2012:391567. [PMID: 23150824 DOI: 10.1155/2012/391567] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
48 Powell A, McNeil J. Primary sclerosing cholangitis associated with CREST (calcinosis, Raynaud phenomenon, oesophageal dysmotility, sclerodactyly and telangiectasia) in an elderly woman: a case report. J Med Case Rep 2015;9:272. [PMID: 26607041 DOI: 10.1186/s13256-015-0747-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
49 Hickey GL, Parvu V, Zhang Y, Cooper CK, Wan Y. A pragmatic approach for dynamically incorporating predicate device data in prospective diagnostic test studies. J Biopharm Stat 2022;:1-13. [PMID: 35649152 DOI: 10.1080/10543406.2022.2080690] [Reference Citation Analysis]
50 Kitahata S, Yamamoto Y, Yoshida O, Tokumoto Y, Kawamura T, Furukawa S, Kumagi T, Hirooka M, Takeshita E, Abe M, Ikeda Y, Hiasa Y. Ileal mucosa-associated microbiota overgrowth associated with pathogenesis of primary biliary cholangitis. Sci Rep 2021;11:19705. [PMID: 34611265 DOI: 10.1038/s41598-021-99314-9] [Reference Citation Analysis]
51 Mago S, Wu GY. Primary Sclerosing Cholangitis and Primary Biliary Cirrhosis Overlap Syndrome: A Review. J Clin Transl Hepatol 2020;8:336-46. [PMID: 33083257 DOI: 10.14218/JCTH.2020.00036] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
52 Medina JF. Role of the Anion Exchanger 2 in the Pathogenesis and Treatment of Primary Biliary Cirrhosis. Dig Dis 2011;29:103-12. [DOI: 10.1159/000324144] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 2.4] [Reference Citation Analysis]
53 Darrat M, Likinyo H, Winata SR, Morgan S, Courtney AE, Lindsay J. Successful living kidney donation from a patient with a Gitelman's syndrome. BMJ Case Rep 2022;15:e246162. [PMID: 35131782 DOI: 10.1136/bcr-2021-246162] [Reference Citation Analysis]
54 Frech T, Novak K, Revelo MP, Murtaugh M, Markewitz B, Hatton N, Scholand MB, Frech E, Markewitz D, Sawitzke AD. Low-dose naltrexone for pruritus in systemic sclerosis. Int J Rheumatol 2011;2011:804296. [PMID: 21918649 DOI: 10.1155/2011/804296] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
55 Banales JM, Sáez E, Uriz M, Sarvide S, Urribarri AD, Splinter P, Tietz Bogert PS, Bujanda L, Prieto J, Medina JF, LaRusso NF. Up-regulation of microRNA 506 leads to decreased Cl-/HCO3- anion exchanger 2 expression in biliary epithelium of patients with primary biliary cirrhosis. Hepatology 2012;56:687-97. [PMID: 22383162 DOI: 10.1002/hep.25691] [Cited by in Crossref: 151] [Cited by in F6Publishing: 138] [Article Influence: 15.1] [Reference Citation Analysis]
56 Smyk DS, Bogdanos DP, Kriese S, Billinis C, Burroughs AK, Rigopoulou EI. Urinary tract infection as a risk factor for autoimmune liver disease: From bench to bedside. Clinics and Research in Hepatology and Gastroenterology 2012;36:110-21. [DOI: 10.1016/j.clinre.2011.07.013] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 2.7] [Reference Citation Analysis]
57 Bogdanos DP, Komorowski L. Disease-specific autoantibodies in primary biliary cirrhosis. Clin Chim Acta. 2011;412:502-512. [PMID: 21185272 DOI: 10.1016/j.cca.2010.12.019] [Cited by in Crossref: 67] [Cited by in F6Publishing: 64] [Article Influence: 5.6] [Reference Citation Analysis]
58 Lin P, Jiang CM. Latest advances in diagnosis of autoimmune liver disease. Shijie Huaren Xiaohua Zazhi 2016; 24(29): 4085-4091 [DOI: 10.11569/wcjd.v24.i29.4085] [Reference Citation Analysis]
59 Bickels J, Weinstein T, Robinson D, Nevo Z. Common Skeletal Growth Retardation Disorders Resulting from Abnormalities within the Mesenchymal Stem Cells Reservoirs in the Epiphyseal Organs Pertaining to the Long Bones. Journal of Pediatric Endocrinology and Metabolism 2010;23. [DOI: 10.1515/jpem.2010.176] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
60 Nakajima K, Oshida H, Muneyuki T, Saito M, Hori Y, Fuchigami H, Kakei M, Munakata H. Independent association between low serum amylase and non-alcoholic fatty liver disease in asymptomatic adults: a cross-sectional observational study. BMJ Open 2013;3:e002235. [PMID: 23293250 DOI: 10.1136/bmjopen-2012-002235] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
61 Mortazavi H, Baharvand M, Movahhedian A, Mohammadi M, Khodadoustan A. Xerostomia due to systemic disease: a review of 20 conditions and mechanisms. Ann Med Health Sci Res 2014;4:503-10. [PMID: 25221694 DOI: 10.4103/2141-9248.139284] [Cited by in Crossref: 42] [Cited by in F6Publishing: 30] [Article Influence: 5.3] [Reference Citation Analysis]
62 Garg D, Nagar A, Philips S, Takahashi N, Prasad SR, Shanbhogue AK, Sahani DV. Immunological diseases of the pancreatico-hepatobiliary system: update on etiopathogenesis and cross-sectional imaging findings. Abdom Imaging 2012;37:261-74. [PMID: 21597892 DOI: 10.1007/s00261-011-9759-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
63 Tang HH, Chen YJ, Tong GD, Zhou DQ, He JS, Zhou XZ, Zheng YJ. Efficacy of ursodeoxycholic acid combined with Tongdan Decoction in treatment of patients with primary biliary cirrhosis. Shijie Huaren Xiaohua Zazhi 2008; 16(13): 1417-1424 [DOI: 10.11569/wcjd.v16.i13.1417] [Cited by in CrossRef: 2] [Article Influence: 0.1] [Reference Citation Analysis]
64 Chen HW, Huang HH, Lai CH, Chang WE, Shih YL, Chang WK, Hsieh TY, Chu HC. Hepatitis C virus infection in patients with primary biliary cirrhosis. Ann Hepatol. 2013;12:78-84. [PMID: 23293197 DOI: 10.1016/s1665-2681(19)31388-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]